Engineered platelets-based drug delivery platform for targeted thrombolysis
Thrombolytic agents have thus far yielded limited therapeutic benefits in the treatment of thrombotic disease due to their short half-life, low targeting ability, and association with serious adverse reactions, such as bleeding complications. Inspired by the natural roles of platelets during thrombu...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-04-01
|
| Series: | Acta Pharmaceutica Sinica B |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S221138352200017X |
| _version_ | 1818126472007647232 |
|---|---|
| author | Songli Wang Ruifeng Wang Nana Meng Linwei Lu Jun Wang Jianfen Zhou Jiasheng Lu Qianzhu Xu Cao Xie Changyou Zhan Yao Li Yang Yu Weiyue Lu Min Liu |
| author_facet | Songli Wang Ruifeng Wang Nana Meng Linwei Lu Jun Wang Jianfen Zhou Jiasheng Lu Qianzhu Xu Cao Xie Changyou Zhan Yao Li Yang Yu Weiyue Lu Min Liu |
| author_sort | Songli Wang |
| collection | DOAJ |
| description | Thrombolytic agents have thus far yielded limited therapeutic benefits in the treatment of thrombotic disease due to their short half-life, low targeting ability, and association with serious adverse reactions, such as bleeding complications. Inspired by the natural roles of platelets during thrombus formation, we fabricated a platelet-based delivery system (NO@uPA/PLTs) comprising urokinase (uPA) and arginine (Arg) for targeted thrombolysis and inhibition of re-embolism. The anchoring of uPA to the platelet surface by lipid insertion increased the thrombotic targeting and in vivo circulation duration of uPA without disturbing platelet functions. Nitric oxide (NO) generated by the loaded Arg inhibited platelet aggregation and activation at the damaged blood vessel, thereby inhibiting re-embolism. NO@uPA/PLTs effectively accumulated at the thrombi in pulmonary embolism and carotid artery thrombosis model mice and exerted superior thrombolytic efficacy. In addition, the platelet delivery system showed excellent thrombus recurrence prevention ability in a mouse model of secondary carotid artery injury. The coagulation indicators in vivo showed that the platelet-based uPA and NO co-delivery system possessed a low hemorrhagic risk, providing a promising tool for rapid thrombolysis and efficient inhibition of posttreatment re-embolism. |
| first_indexed | 2024-12-11T07:02:00Z |
| format | Article |
| id | doaj.art-b8b1fbaf2ef344b191bfd6d943de062b |
| institution | Directory Open Access Journal |
| issn | 2211-3835 |
| language | English |
| last_indexed | 2024-12-11T07:02:00Z |
| publishDate | 2022-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Acta Pharmaceutica Sinica B |
| spelling | doaj.art-b8b1fbaf2ef344b191bfd6d943de062b2022-12-22T01:16:37ZengElsevierActa Pharmaceutica Sinica B2211-38352022-04-0112420002013Engineered platelets-based drug delivery platform for targeted thrombolysisSongli Wang0Ruifeng Wang1Nana Meng2Linwei Lu3Jun Wang4Jianfen Zhou5Jiasheng Lu6Qianzhu Xu7Cao Xie8Changyou Zhan9Yao Li10Yang Yu11Weiyue Lu12Min Liu13Department of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery (Ministry of Education and PLA), Fudan University, Shanghai 201203, China; Department of Pharmacology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, ChinaDepartment of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery (Ministry of Education and PLA), Fudan University, Shanghai 201203, ChinaDepartment of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery (Ministry of Education and PLA), Fudan University, Shanghai 201203, ChinaThe Department of Integrative Medicine, Huashan Hospital, Fudan University and the Institutes of Integrative Medicine of Fudan University, Shanghai 200041, ChinaDepartment of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery (Ministry of Education and PLA), Fudan University, Shanghai 201203, ChinaDepartment of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery (Ministry of Education and PLA), Fudan University, Shanghai 201203, ChinaDepartment of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery (Ministry of Education and PLA), Fudan University, Shanghai 201203, ChinaDepartment of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery (Ministry of Education and PLA), Fudan University, Shanghai 201203, ChinaDepartment of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery (Ministry of Education and PLA), Fudan University, Shanghai 201203, ChinaDepartment of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery (Ministry of Education and PLA), Fudan University, Shanghai 201203, China; Department of Pharmacology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, ChinaThe National Facility for Protein Science in Shanghai (NFPS), Shanghai 201210, ChinaThe National Facility for Protein Science in Shanghai (NFPS), Shanghai 201210, ChinaDepartment of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery (Ministry of Education and PLA), Fudan University, Shanghai 201203, China; State Key Laboratory of Medical Neurobiology and the Collaborative Innovation Center for Brain Science and Department of Pharmacology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China; Minhang Branch, Zhongshan Hospital and Institute of Fudan-Minhang Academic Health System, Minhang Hospital, Fudan University, Shanghai 201199, China; Corresponding authors. Tel./fax: +86 21 51980090 (Weiyue Lu); +86 21 51980092 (Min Liu).Department of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery (Ministry of Education and PLA), Fudan University, Shanghai 201203, China; Corresponding authors. Tel./fax: +86 21 51980090 (Weiyue Lu); +86 21 51980092 (Min Liu).Thrombolytic agents have thus far yielded limited therapeutic benefits in the treatment of thrombotic disease due to their short half-life, low targeting ability, and association with serious adverse reactions, such as bleeding complications. Inspired by the natural roles of platelets during thrombus formation, we fabricated a platelet-based delivery system (NO@uPA/PLTs) comprising urokinase (uPA) and arginine (Arg) for targeted thrombolysis and inhibition of re-embolism. The anchoring of uPA to the platelet surface by lipid insertion increased the thrombotic targeting and in vivo circulation duration of uPA without disturbing platelet functions. Nitric oxide (NO) generated by the loaded Arg inhibited platelet aggregation and activation at the damaged blood vessel, thereby inhibiting re-embolism. NO@uPA/PLTs effectively accumulated at the thrombi in pulmonary embolism and carotid artery thrombosis model mice and exerted superior thrombolytic efficacy. In addition, the platelet delivery system showed excellent thrombus recurrence prevention ability in a mouse model of secondary carotid artery injury. The coagulation indicators in vivo showed that the platelet-based uPA and NO co-delivery system possessed a low hemorrhagic risk, providing a promising tool for rapid thrombolysis and efficient inhibition of posttreatment re-embolism.http://www.sciencedirect.com/science/article/pii/S221138352200017XPlateletUrokinaseNitric oxideTargeted thrombolysisThrombus reformation |
| spellingShingle | Songli Wang Ruifeng Wang Nana Meng Linwei Lu Jun Wang Jianfen Zhou Jiasheng Lu Qianzhu Xu Cao Xie Changyou Zhan Yao Li Yang Yu Weiyue Lu Min Liu Engineered platelets-based drug delivery platform for targeted thrombolysis Acta Pharmaceutica Sinica B Platelet Urokinase Nitric oxide Targeted thrombolysis Thrombus reformation |
| title | Engineered platelets-based drug delivery platform for targeted thrombolysis |
| title_full | Engineered platelets-based drug delivery platform for targeted thrombolysis |
| title_fullStr | Engineered platelets-based drug delivery platform for targeted thrombolysis |
| title_full_unstemmed | Engineered platelets-based drug delivery platform for targeted thrombolysis |
| title_short | Engineered platelets-based drug delivery platform for targeted thrombolysis |
| title_sort | engineered platelets based drug delivery platform for targeted thrombolysis |
| topic | Platelet Urokinase Nitric oxide Targeted thrombolysis Thrombus reformation |
| url | http://www.sciencedirect.com/science/article/pii/S221138352200017X |
| work_keys_str_mv | AT songliwang engineeredplateletsbaseddrugdeliveryplatformfortargetedthrombolysis AT ruifengwang engineeredplateletsbaseddrugdeliveryplatformfortargetedthrombolysis AT nanameng engineeredplateletsbaseddrugdeliveryplatformfortargetedthrombolysis AT linweilu engineeredplateletsbaseddrugdeliveryplatformfortargetedthrombolysis AT junwang engineeredplateletsbaseddrugdeliveryplatformfortargetedthrombolysis AT jianfenzhou engineeredplateletsbaseddrugdeliveryplatformfortargetedthrombolysis AT jiashenglu engineeredplateletsbaseddrugdeliveryplatformfortargetedthrombolysis AT qianzhuxu engineeredplateletsbaseddrugdeliveryplatformfortargetedthrombolysis AT caoxie engineeredplateletsbaseddrugdeliveryplatformfortargetedthrombolysis AT changyouzhan engineeredplateletsbaseddrugdeliveryplatformfortargetedthrombolysis AT yaoli engineeredplateletsbaseddrugdeliveryplatformfortargetedthrombolysis AT yangyu engineeredplateletsbaseddrugdeliveryplatformfortargetedthrombolysis AT weiyuelu engineeredplateletsbaseddrugdeliveryplatformfortargetedthrombolysis AT minliu engineeredplateletsbaseddrugdeliveryplatformfortargetedthrombolysis |